{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-26-000018","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.732956+00:00","generated_at":"2026-05-15T23:38:57.467434+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Novocure reports Q4 2025 revenues up 8% to $174M; FDA approves Optune Pax for pancreatic cancer","bullets":["FDA approved Optune Pax for locally advanced pancreatic cancer in Feb 2026; expands addressable market significantly.","Q4 2025 net revenue $174.4M (+8% YoY); full year $655.4M (+8%). Q4 net loss $24.5M ($0.22 loss per share).","2026 guidance: revenue $675-705M; Adjusted EBITDA ($20M)-$0M; Optune Lua/Pax revenue $15-25M.","Frank Leonard appointed CEO Dec 2025; CMO Nicolas Leupin resigned Feb 2026; CMS billing privileges reinstated.","Active patients on TTFields therapy globally totaled 4,620 at Dec 31, 2025; GBM prescriptions up 6%."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-26-000018","json":"https://secwatch.observer/filing/0001645113-26-000018.json","markdown":"https://secwatch.observer/filing/0001645113-26-000018.md","text":"https://secwatch.observer/filing/0001645113-26-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000018/0001645113-26-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000018/nvcr-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:38:57.467434+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}